4D Pharma Is Latest Biotech Casualty After Creditor Calls Time

Third NASDAQ-Listed Biotech To Cease Trading In 2022

 
• By Andrew McConaghie
NASDAQ down
4D Pharma's demise is a symptom of the deep and prolonged bear market in early stage listed biotech sector. • Source: Shutterstock

More from Business

More from Scrip